What is Insulet's free cash flow?

Insulet (PODD) reported free cash flow of $89.5M in Q1 2026.

How has Insulet's free cash flow changed year-over-year?

Insulet's free cash flow increased by 73.8% year-over-year, from $51.5M to $89.5M.

What is the long-term trend for Insulet's free cash flow?

Over 3 years (2021 to 2025), Insulet's free cash flow has grown at a 28.0% compound annual growth rate (CAGR), from -$180M to $377.7M.

Insulet PODD Free cash flow

Free cash flow at other companies

Eli LillyLLY

$3.01B+1,828%

MedtronicMDT

$2.09B+0.8%

AbbottABT

$916M-1.8%

West Pharmaceutical ServicesWST

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

See full

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

See full

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Valuation

See full

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

See full

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

See full

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Calculated from Insulet’s reported figures.

$113.8Mnet cash from operating−$24.3Mcapital expenditures=$89.5M

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's free cash flow?: Insulet (PODD) reported free cash flow of $89.5M in Q1 2026.
How has Insulet's free cash flow changed year-over-year?: Insulet's free cash flow increased by 73.8% year-over-year, from $51.5M to $89.5M.
What is the long-term trend for Insulet's free cash flow?: Over 3 years (2021 to 2025), Insulet's free cash flow has grown at a 28.0% compound annual growth rate (CAGR), from -$180M to $377.7M.